PE55998A1 - Derivados 19-nor-pregneno substituidos - Google Patents

Derivados 19-nor-pregneno substituidos

Info

Publication number
PE55998A1
PE55998A1 PE1997000035A PE00003597A PE55998A1 PE 55998 A1 PE55998 A1 PE 55998A1 PE 1997000035 A PE1997000035 A PE 1997000035A PE 00003597 A PE00003597 A PE 00003597A PE 55998 A1 PE55998 A1 PE 55998A1
Authority
PE
Peru
Prior art keywords
hydrogen
formula
alkyl
compounds
refer
Prior art date
Application number
PE1997000035A
Other languages
English (en)
Inventor
Jean Lafay
Jacques Paris
Jean-Claude Pascal
Alain Piasco
Remi Delansorne
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of PE55998A1 publication Critical patent/PE55998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: "X" ES OXIGENO O UN GRUPO FUNCIONAL HIDROXIIMINO; R1, R2, R3 Y R4 SON HIDROGENO O ALQUILO C1-C6, EN DONDE: SI n ES CERO, DOS DE R1, R2, R3 Y R4 NO SON HIDROGENO, SI n ES UNO, R3 Y R4 NO SON SIMULTANEAMENTE HIDROGENO; R5 ES PREFERENTEMENTE -COR7, EN DONDE R7 ES ALQUILO C1-C6; R6 ES PREFERENTEMENTE HIDROGENO. TAMBIEN SE REFIEREN A LAS COMPOSICIONES QUE COMPRENDEN AL COMPUESTO DE FORMULA (I) COMO PRINCIPIO ACTIVO SOLO, PARA TRATAR LOS TRANSTORNOS GINECOLOGICOS ASOCIADOS CON UN DESEQUILIBRIO ESTROGENO/PROGESTERONA O PARA INHIBIR LAS SECRECIONES GONADOTROPICAS/GONADALES, O EN COMBINACION CON UN ESTEROIDE SEXUAL, COMO ANTICONCEPTIVO, O CON UN ESTROGENO, PARA EL TRATAMIENTO DE REEMPLAZO HORMONAL POST-MENOPAUSICO. ESTOS COMPUESTOS DE FORMULA (I) HAN DESARROLLADO UNA POTENTE ACTIVIDAD PROGESTAGENA SIN PRESENTAR ACTIVIDAD ANDROGENICA RESIDUAL
PE1997000035A 1996-01-22 1997-01-22 Derivados 19-nor-pregneno substituidos PE55998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives

Publications (1)

Publication Number Publication Date
PE55998A1 true PE55998A1 (es) 1998-10-01

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000035A PE55998A1 (es) 1996-01-22 1997-01-22 Derivados 19-nor-pregneno substituidos

Country Status (36)

Country Link
US (1) US6180803B1 (es)
EP (2) EP0785212A1 (es)
JP (2) JP4368945B2 (es)
KR (1) KR100396902B1 (es)
CN (1) CN1187366C (es)
AP (1) AP1176A (es)
AR (1) AR005500A1 (es)
AT (1) ATE184015T1 (es)
BR (1) BR9707064A (es)
CA (1) CA2243504C (es)
CO (1) CO4810230A1 (es)
CZ (1) CZ292047B6 (es)
DE (1) DE69700470T2 (es)
DZ (1) DZ2169A1 (es)
EE (1) EE03692B1 (es)
ES (1) ES2140961T3 (es)
GR (1) GR3031954T3 (es)
HK (1) HK1018216A1 (es)
HU (1) HU221796B1 (es)
ID (1) ID15840A (es)
IL (1) IL125379A (es)
IS (1) IS1902B (es)
JO (1) JO1971B1 (es)
MY (1) MY116845A (es)
NO (1) NO309572B1 (es)
NZ (1) NZ330954A (es)
OA (1) OA10813A (es)
PE (1) PE55998A1 (es)
PL (1) PL185608B1 (es)
RU (1) RU2166509C2 (es)
SI (1) SI0886645T1 (es)
TN (1) TNSN97015A1 (es)
TR (1) TR199801399T2 (es)
TW (1) TW411345B (es)
WO (1) WO1997027210A1 (es)
ZA (1) ZA97521B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
AR028110A1 (es) * 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
CA2537702C (en) 2003-09-03 2012-01-03 Miscon Trading S.A. Methods for the treatment of endometriosis
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109364020B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
HK1018216A1 (en) 1999-12-17
HUP9900684A3 (en) 1999-11-29
SI0886645T1 (en) 1999-12-31
JP4368945B2 (ja) 2009-11-18
CA2243504C (en) 2004-03-30
OA10813A (en) 2003-01-28
PL327998A1 (en) 1999-01-04
ATE184015T1 (de) 1999-09-15
IS4800A (is) 1998-07-21
GR3031954T3 (en) 2000-03-31
RU2166509C2 (ru) 2001-05-10
EE9800219A (xx) 1998-12-15
EP0886645A1 (en) 1998-12-30
EP0785212A1 (en) 1997-07-23
AR005500A1 (es) 1999-06-23
DE69700470D1 (de) 1999-10-07
DE69700470T2 (de) 2000-03-30
AU1595597A (en) 1997-08-20
BR9707064A (pt) 1999-12-28
IL125379A (en) 2003-05-29
NO983356L (no) 1998-07-21
US6180803B1 (en) 2001-01-30
AU708135B2 (en) 1999-07-29
CA2243504A1 (en) 1997-07-31
JP2009167188A (ja) 2009-07-30
NO309572B1 (no) 2001-02-19
ZA97521B (en) 1997-08-04
PL185608B1 (pl) 2003-06-30
CN1209811A (zh) 1999-03-03
NZ330954A (en) 1998-10-28
TNSN97015A1 (fr) 2005-03-15
NO983356D0 (no) 1998-07-21
CZ230798A3 (cs) 1998-11-11
JO1971B1 (en) 1997-12-15
HU221796B1 (hu) 2003-01-28
KR19990081895A (ko) 1999-11-15
CN1187366C (zh) 2005-02-02
EP0886645B1 (en) 1999-09-01
AP1176A (en) 2003-06-30
JP2000503980A (ja) 2000-04-04
AP9801299A0 (en) 1998-09-30
HUP9900684A2 (hu) 1999-07-28
TR199801399T2 (xx) 1998-10-21
WO1997027210A1 (en) 1997-07-31
CO4810230A1 (es) 1999-06-30
TW411345B (en) 2000-11-11
IL125379A0 (en) 1999-03-12
ID15840A (id) 1997-08-14
MY116845A (en) 2004-04-30
CZ292047B6 (cs) 2003-07-16
ES2140961T3 (es) 2000-03-01
IS1902B (is) 2003-11-20
DZ2169A1 (fr) 2002-12-25
EE03692B1 (et) 2002-04-15
KR100396902B1 (ko) 2004-05-03

Similar Documents

Publication Publication Date Title
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
EA199900989A1 (ru) Нестероидные (гетеро)циклически замещенные ациланилиды, обладающие смешанным гестагенным и андрогенным действием
UY27437A1 (es) Compuestos químicos
CY1108093T1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
BR9709427A (pt) Oxa ácidos e compostos relacionados para tratamento de condições da pele
EA200201052A1 (ru) 8β-ГИДРОКАРБИЛЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ
TR200302320T4 (tr) Benzazol türevleri ve bunların jnk modülatörleri olarak kullanımları
ES2109995T3 (es) Procedimiento y composiciones de contracepcion y de tratamiento de alteraciones ginecologicas benignas.
UY27436A1 (es) Compuestos químicos
EP0845985A4 (en) NON-STEROIDIAN SULFATASE INHIBITOR COMPOUNDS AND METHODS OF USE
HUP0200714A2 (hu) Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
MY114394A (en) Estra-1,3,5 (10)-trien derivatives,process for their preparation and pharmaceutical compositions containing these compounds
ATE233724T1 (de) Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel
HUP0002951A2 (hu) Proteáz inhibitor hatású Disz(amino-metil)-keton-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
NO159278C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-alkyl-androsta-1,4-dien-3,17-dioner.
GB2380939B (en) Treatment or prevention of auto-immune diseases
AR007012A1 (es) Compuestos de 2-fenil-3-benzoil-benzotiofenos, composiciones farmaceuticas que los contienen y el uso de dichos compuestos para el tratamiento del sindrome postmenopausico, inhibicion del cancer estrogenodependiente, entre otras afecciones patologicas
ES2164400T3 (es) Esteroides con actividad anticonceptiva y antiosteoporotica.
EA200401544A1 (ru) 9α-ЗАМЕЩЁННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ
ATE277913T1 (de) Bisarylderivate mit fsh rezeptor modulierender aktivität
PE20011215A1 (es) Estratrienos sustituidos como estrogenos selectivamente activos
HUP0301592A2 (hu) 16alfa-metil- vagy etil-szubsztituált ösztrogének és ezeket tartalmazó gyógyszerkészítmények
AR034194A1 (es) Un compuesto esteroide, su uso, una composicion farmaceutica que lo comprende y un kit para la anticoncepcion masculina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed